# Predicting the Response to Montelukast by Genetic Variation in Asthmatics

> **NCT00116324** · PHASE3 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 150 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Montelukast

## Key facts

- **NCT ID:** NCT00116324
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 150 (—)
- **Last updated:** 2021-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116324, "Predicting the Response to Montelukast by Genetic Variation in Asthmatics". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00116324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*